Table 2.
All patients: increased detection of Barrett's esophagus or dysplasia
| Forceps biopsy results | |||||
|---|---|---|---|---|---|
| WATS results | HGD/EAC | IND/LGD | NDBE | No BE | Total |
| HGD/EAC | 8 | 1 | 5 | 5 | 19 |
| IND/LGD | 3 | 17 | 110 | 93 | 223 |
| NDBE | 1 | 40 | 928 | 2,570 | 3,539 |
| Negative | 1 | 17 | 641 | 8,459 | 9,118 |
| Total | 13 | 75 | 1,684 | 11,127 | 12,899 |
| Increased detection with WATS | |||||
| Relative increase vs. forceps | Absolute increase vs. forceps | Number needed to test | |||
| All Barrett's esophagus | 153% (95% CI: 144%–162%) | 19.9% | 5.0 | ||
| Dysplastic Barrett's | 242% (95% CI: 191%–315%) | 1.7% | 60.6 | ||
BE, Barrett's esophagus EAC, esophageal adenocarcinoma; HGD, high-grade dysplasia; IND, indefinite for dysplasia; LGD, low-grade dysplasia.